leon-nanodrugs GmbH, a Munich, Germany-based enabler of nano technology for the pharmaceutical industry, completed a Series B funding round of undisclosed amount.
Backers included TVM Life Science Innovation I.L.P., CD-Venture GmbH, Albany Private Equity Holdings Pty Ltd, Eckenstein-Geigy-Stiftung, LOF Leon Partnership, L.P., Evotec SE and BayBG.
The company intends to use the funds to further strengthen its leadership position in the provision of nano solutions for the pharmaceutical and biotechnology industries.
Led by Andrea Cusack, CEO, leon delivers novel, validated and optimized solutions for enhanced bioavailability, increased solubility and improved stability, revitalizing forgotten formulations, and breathing new life into generics. Its proprietary * MicroJet Reactor (MJR) technology platforms offer access to SMART nanoparticles™ and nano-formulated drugs, which add value at every stage of the chain from partners and payers to caregivers and patients. Under a separate partnership deal, Evotec and leon will leverage their combined expertise in nano-medicine development services, providing clients with opportunities within the CDMO sector. Together, the partnership will maximize the effectiveness of clinical and commercial nano-medicine development and co-operate on carefully selected development programs. Enno Spillner, CFO of Evotec and Dr. Peter Graf, Investment Manager of BayBG will join a peer recognized supervisory board which includes Dr. Hubert Birner (Managing Partner of TVM Life Science Venture Capital), Dr Gerhard Ries (LifeCare Partners), James C. Gale (Signet Healthcare Partners) and Dr. Frank Mathias (Rentschler Biotechnologie GmbH).